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Introduction
Treatment of  early-stage cancer, including surgery, hormone therapy, and chemotherapy, has improved 
substantially, but preventing metastasis remains a more elusive target. Breast cancer, the most common 
malignancy in women, recurs in 1 of  5 patients, despite ideal therapy. Luminal breast cancer, the most 
common type of  breast cancer, preferentially metastasizes to bone while lungs and liver represent the sec-
ond and third most common sites (1, 2). Understanding the microenvironment of  these tissues is likely to 
provide insights into their predisposition for cancer seeding.
Obesity is expected to affect 1 in 2 adults by 2030 (3) and is associated with increased incidence of  at 
least 13 types of  cancer (4) and poorer prognosis (5); yet the mechanisms of  these associations remain unre-
solved. There is, however, experimental evidence that the products of  adipocytes, juxtaposed to the tumor, 
promote its growth. The means by which obese adipocytes enhance tumor growth is postulated to involve 
inflammatory factors, fatty acid transfer, and/or direct interaction with the tumor (6).
The skeleton is the primary target of  metastatic breast cancer, but the relationship between bone mass 
and metastatic predisposition is unknown. To address this issue, we turned to DTA-Stop-flox-Adipoq Cre 
“fat-free” (FF) mice, which lack brown adipose tissue (BAT) and white adipose tissue (WAT) via germline 
depletion (7) and are substantially osteosclerotic. However, we found no effect of  enhanced bone mass on 
breast cancer metastasis to the skeleton. The mice in which we tested this hypothesis have severe hepatic 
steatosis, and surprisingly, it and a variety of  other models of  nonalcoholic fatty liver disease (NAFLD) 
have a marked predisposition to liver metastasis, which is unusual in nonsteatotic mice. Thus, patholog-
ical lipid accumulation has the capacity to profoundly increase liver metastasis. Furthermore, it appears 
that in contrast to previous reports implicating inflammation (8), uncomplicated steatosis promotes liver 
metastasis by providing the products of  lipolysis as a source of  energy, which is used by tumor cells mainly 
via mitochondrial oxidation. Importantly, the histology of  human liver metastasis suggests the same may 
Obesity predisposes to cancer and a virtual universality of nonalcoholic fatty liver disease (NAFLD). 
However, the impact of hepatic steatosis on liver metastasis is enigmatic. We find that while 
control mice were relatively resistant to hepatic metastasis, those which were lipodystrophic or 
obese, with NAFLD, had a dramatic increase in breast cancer and melanoma liver metastases. 
NAFLD promotes liver metastasis by reciprocal activation initiated by tumor-induced triglyceride 
lipolysis in juxtaposed hepatocytes. The lipolytic products are transferred to cancer cells via fatty 
acid transporter protein 1, where they are metabolized by mitochondrial oxidation to promote 
tumor growth. The histology of human liver metastasis indicated the same occurs in humans. 
Furthermore, comparison of isolates of normal and fatty liver established that steatotic lipids 
had enhanced tumor-stimulating capacity. Normalization of glucose metabolism by metformin 
did not reduce steatosis-induced metastasis, establishing the process is not mediated by the 
metabolic syndrome. Alternatively, eradication of NAFLD in lipodystrophic mice by adipose tissue 
transplantation reduced breast cancer metastasis to that of control mice, indicating the steatosis-
induced predisposition is reversible.
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occur in humans. Thus, a reciprocal activating relationship exists between steatotic hepatocytes and meta-
static cancer. In this circumstance, tumor induces lipolysis of  hepatic triglycerides, which are transferred to 
cancer cells and ultimately serve as an energy source for tumor growth. Given steatosis is preventable and 
we find its eradication eliminates metastatic predisposition, if  our observations translate to patients, the 
implications would be significant.
Results
Steatotic mice are predisposed to hepatic metastasis. Given the substantial osteosclerosis in FF mice, they provid-
ed an opportunity for determining the effects of  increased bone mass on skeletal metastasis. We therefore 
administered osteolytic PyMT-Bo1-GFP-Luc (Bo1) breast adenocarcinoma cells, via intracardiac injection, 
to FF mice, which exhibit a virtually complete depletion of  WAT and BAT, as well as to their Cre littermates 
(Con) (7). Contrary to our hypothesis, 12 days after injection, skeletal metastases, determined by in vivo 
and ex vivo bioluminescence imaging (BLI) and histology, were indistinguishable in fat-depleted and con-
trol mice (Figure 1, A, B, and D; and Supplemental Figure 1; supplemental material available online with 
this article; https://doi.org/10.1172/jci.insight.136215DS1). The same held true regarding lung and kidney 
tumor abundance. While BLI and gross and microscopic examination revealed a paucity of  hepatic metas-
tasis in control mice, breast cancer was abundant in the livers of  FF mice (Figure 1, A–D). To confirm the 
association of  lipodystrophy and hepatic metastasis, we administered Bo1 cancer cells to mice conditionally 
deleted of  PPARγ, which is essential for adipocyte differentiation in all fat depots, using adiponectin-Cre 
(PPAR ADQ). In fact, the liver-predominant metastatic pattern of  both lipodystrophic models was indistin-
guishable (Figure 1).
Circulating leptin and adiponectin are virtually undetectable in FF mice (7). Because both adipokines 
are reported to suppress metastasis (9, 10), their absence presented as possible mediators of  lipodystrophic 
predisposition to hepatic tumor. To address this issue, we delivered Bo1 cancer cells to leptin–/– (ob/ob) or 
adiponectin–/– mice. While the absence of  adiponectin had no effect on hepatic tumor abundance (Supple-
mental Figure 2), liver metastasis of  leptin-deficient mice mirrored FF, although they also had an increased 
abundance of  lung tumors (Figure 2, A and B). To further explore the possible role of  leptin deficiency in 
promoting steatosis-enhanced metastasis, we administered breast cancer cells to mice fed a high-fat diet 
(HFD) for 12 weeks, producing obesity. In fact, diet-induced obesity, wherein circulating leptin is increased, 
yielded the same predisposition to hepatic metastasis as deficiency of  the adipokine in ob/ob mice (Figure 2, 
C and D). Combined with the fact that Bo1 cells did not express the leptin receptor but bore the adiponectin 
receptor, it appears that deficiency of  these adipokines, in FF mice, does not mediate liver metastasis.
In keeping with their lipodystrophic state, FF and PPAR ADQ (11) mice are steatotic, raising the pos-
sibility that NAFLD promotes metastasis. The fact that all models with enhanced metastasis have severe 
hepatic steatosis while adiponectin–/– mice, which have normal livers, mirror control supports this hypothe-
sis. This distinction raised the possibility that liver lipids contribute to the organ’s metastatic predisposition 
and that reversal of  steatosis in FF mice would reduce tumor abundance. To this end, we transplanted WAT 
into FF mice, which eradicates fatty liver disease (7) and eliminates enhanced susceptibility to hepatic breast 
cancer metastasis (Figure 2, E and F). WAT transplantation also normalizes the metabolic syndrome in FF 
mice (7), raising the possibility that elimination of  hyperglycemia and hyperinsulinemia, both implicated 
in cancer growth, mediates the reversal of  metastatic predisposition (12–14). To determine if  metabolic 
abnormalities likely contribute to steatotic liver metastasis, we fed FF mice metformin, standard therapy for 
lipodystrophy-associated diabetes. While the drug normalizes glucose tolerance and significantly reduces 
circulating insulin (7), it did not decrease tumor liver metastasis of  FF mice (Figure 2G). Thus, increased 
tumor metastasis in steatotic livers likely does not reflect mice’s metabolic dysfunction. Finally, intracardiac 
injection of  a second tumor model, B16 melanoma cells, generated markedly increased hepatic tumor nod-
ules similar to breast cancer (Supplemental Figure 3). Thus, the predisposition to steatotic liver metastasis is 
not restricted to breast cancer.
Transfer of  steatotic lipids to tumor. The predisposition to metastasis of  many models of  steatosis, includ-
ing those that are lipodystrophic or obese, raised the possibility that a liver-residing tumor uses hepatic 
lipids as an energy source. Consistent with transfer from hepatocytes to cancer, the amount of  lipid in 
areas distant from tumor nodules was indistinguishable from non–tumor-injected counterparts while it 
was markedly reduced in regions juxtaposed to cancer (Figure 3, A and B). Importantly, the same held 
true in patients (Figure 3C). Conversely, lipid droplets were ultrastructurally more abundant in cancer cells 
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residing in steatotic than in normal liver (Figure 3, D and E). To confirm transfer of  lipids from liver to 
tumor cells, the hepatocyte cell line HepG2 was incubated with the fluorescent fatty acid analog, BODIPY. 
The HepG2 cells were washed with PBS containing 0.2% fatty acid–free BSA to remove extracellular fatty 
acids and cocultured with mCherry-labeled Bo1– cells. Tumor cells expressing mCherry and BODIPY were 
quantitated with time of  coculture, by flow cytometry (Figure 3F). After 3 hours and 6 hours of  coculture, 
approximately 90% and 80%, respectively, of  Bo1– cells stained with BODIPY. Consistent with metabolism 
Figure 1. Lipodystrophic mice are predisposed to hepatic metastasis. (A–D) Two-month-old FF and Con mice were injected with Bo1 cells via left ventricular 
chamber, and 12 days later tumor burden was analyzed. (A) In vivo BLI image; (B) ex vivo image of liver, bone, lung, and kidney; (C) gross appearance of Con 
and FF liver; and (D) quantification of tumor burden in liver, bone, lung, and kidney of Con and FF mice. n = 8–13. ROI, region of interest. (E–H) Two-month-old 
PPAR ADQ and Con mice were injected with Bo1 cells via left ventricular chamber, and 12 days later tumor burden was analyzed. (E) In vivo BLI image; (F) ex 
vivo image of liver, bone, lung, and kidney; (G) gross appearance of Con and FF liver 12 days after tumor injection; and (H) quantification of tumor burden in 
liver, bone, lung, and kidney of Con and FF mice. n = 7. Data are presented as mean ± SD. **P < 0.01, ***P < 0.001 as determined by unpaired 2-tailed t test.
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by the tumor cells, BODIPY labeling markedly decreased after 12 and 24 hours of  coculture. Confocal 
microscopy confirmed transfer of  BODIPY from HepG2 to Bo1 cells (Figure 3G).
As expected, triacylglycerol (TG) was substantially enhanced in livers of  FF mice (Figure 4A). Further 
supporting the concept of  transfer of  lipids from steatotic liver to cancer cells, TG content of  FF but not WT 
liver, cocultured with Bo1 cells, diminished considerably. Indicating this reduction of  TG reflects lipolysis, adi-
pose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) gene expression, in the livers of  FF mice, 
was also increased after coculture with Bo1 cells but decreased in the naive condition (Figure 4B and Supple-
mental Figure 4). Despite this enhanced expression of  lipolytic enzymes and decreased TG abundance, free 
fatty acid (FFA) content in FF liver, cultured with Bo1 cells, was indistinguishable from control (Figure 4C). 
These observations suggest a scenario in which the products of  accelerated lipolysis of  TG, in steatotic liver, 
Figure 2. Obese mice are predisposed to hepatic metastasis. (A and B) Two-month-old leptin–/– (ob/ob) and control mice were injected with Bo1 
cells via left ventricular chamber, and 12 days later, tumor burden was analyzed. (A) Ex vivo image of liver, bone, lung, and kidney. (B) Quantification 
of tumor burden in liver, bone, lung, and kidney. n = 9–11. (C and D) WT mice were fed chow or HFD for 3 months, after which Bo1 cells were injected 
intracardiacally. (C) Ex vivo image of liver, bone, lung, and kidney and (D) quantification of tumor burden in liver, bone, lung, and kidney 12 days later. 
n = 8–13. (E and F) FF mice were injected intracardiacally with Bo1 cells 6 weeks after fat transplantation. (E) In vivo BLI image and (F) quantification 
of tumor burden in liver 12 days later. n = 8–9. (G) Following 2 months of metformin feeding, FF mice were injected with Bo1 cells. BLI quantification 
of liver tumor burden 12 days after injection. n = 4–5. Data are presented as mean ± SD. **P < 0.01, ***P < 0.001 as determined by unpaired 2-tailed t 
test (B and D) or 1-way ANOVA test with analysis of variance with Holm-Šidák multiple-comparisons test (F and G).
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are transferred to metastatic tumor, where they are metabolized. Consistent with cancer incorporation of  the 
products of  lipolysis, 11C-palmitate uptake by FF liver was significantly enhanced by the presence of  tumor 
(Figure 4, D and E). To further explore the mechanism whereby steatosis promotes lipid uptake by tumor, we 
performed quantitative PCR (qPCR) analysis of  fatty acid transporter proteins (FATPs) in Bo1 cells exposed 
to fatty liver–conditioned medium and found only FATP1, which mediates adipocyte to tumor transport, 
increased (Figure 4F and Supplemental Figure 5) (15). In contrast, CD36, another cancer-activating lipid 
transporter, is undetectable in Bo1 cells regardless of  culture conditions (16).
Steatosis promotes tumor growth and migration. Given our evidence of  transfer of  lipids from steatotic 
hepatocytes to cancer, we turned to its functional implications. Thus, we asked whether coculture with 
Figure 3. Steatotic hepatocytes transfer lipids to tumor. (A) H&E staining of FF steatotic liver before (- tumor) and 12 days after Bo1 intracardiac injection 
(+ tumor). Note the disappearance of steatosis juxtaposed to tumor. Scale bar: 400 μm. T, tumor. (B) Oil red O staining of FF liver 8 days after intracardiac 
injection of Bo1 cells. Arrow indicates disappearance of lipid staining in hepatocytes juxtaposed to tumor. Scale bar: 1 mm. (C) H&E staining of liver of an 
NAFLD patient with breast cancer metastasis demonstrating areas distal (left panel) and proximal (right panel) to tumor. Scale bar: 1 mm. (D) Ultrastructural 
image of Bo1 cells in the liver of control or FF mice 10 days after intracardiac injection. Yellow asterisks indicate lipid droplets. Scale bar: 2 μm. (E) The number 
of lipid droplets inside a single Bo1 cell in the liver of control and FF mice 10 days after intracardiac injection. n = 4–5. (F) Flow cytometric analysis of frequen-
cy of mCherry-labeled Bo1- cells containing BODIPY derived from HepG2 cells after 0, 3, 6, 12, or 24 hours of coculture. n = 3. (G) Confocal Z-stack imaging of 
mCherry-labeled Bo1– cell after 3 hours of coculture with BODIPY-treated HepG2 cells. Ten sections of a confocal Z-stack were obtained through the height of 
the cell. The optical section in the middle of cell is presented. The side image on the merged panel is the cross section, and the top image is the longitudinal 
section of the Bo1– cell present in the middle. The image identifies fluorescence-labeled BODIPY within the tumor cell. Scale bar: 10 μm. Data are presented as 
mean ± SD. ****P < 0.0001 as determined by unpaired 2-tailed t test (E).
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FF or Con liver has distinct morphological effects on Bo1 cells. Consistent with a product of  steatotic 
hepatocytes directly affecting breast cancer, FF liver normalized the altered shape of  tumor cells cultured in 
serum-depleted medium, while Con liver showed no such effect (Figure 5A).
To assess the impact of  steatosis on growth of  liver-residing, metastatic breast cancer, we directly injected 
Bo1 cells into the livers of  FF and control mice. There was substantially more tumor in the steatotic than con-
trol liver 8 days later (Figure 5, B and C). Confirming that tumor abundance in FF injected liver represented 
accelerated cancer cell replication, proliferating cell nuclear antigen (PCNA) was increased (Figure 5D).
To determine if  steatosis enhances the tumor growth–stimulating capacity of lipids, we added equal amounts 
lipids, derived from FF and WT livers, to cultures of Bo1 cells. As indicated by BrdU incorporation and sup-
ported by immunoblots of the mitosis-associated signaling molecules, protein kinase B (AKT) and cyclin D1, 
steatosis enhanced the capacity of lipids to promote tumor growth (Figure 6, A and B). Furthermore, coculture 
with FF liver increased basal mitochondrial respiration of Bo1 cells as indicated by Seahorse oxygen consump-
tion assay (Figure 6C). Consistent with this observation, gene expression of carnitine palmitoyltransferase 1 
(CPT1), a rate-limiting event of mitochondrial β-oxidation, which controls mitochondrial uptake of long-chain 
acyl-CoAs, was upregulated in Bo1 cells cocultured with fatty liver (Figure 6D). Alternatively, CPT1 gene dele-
tion in Bo1 cells decreased tumor growth, in vivo (Figure 6E). Thus, transfer of lipid products from steatotic 
hepatocytes appeared to promote metastatic growth. Likely reflecting robust hepatic gluconeogenesis, FF liver 
also increased the glycolytic activity (extracellular acidification rate; ECAR) of Bo1 cells (Supplemental Figure 
6). Suggesting steatosis also predisposes cancer cell hepatic implantation (i.e., seeding), Transwell coculture doc-
umented more Bo1 cells migrating to the fatty than to the normal liver (Figure 6F). Supporting this concept in 
vivo, BLI documented increased tumor abundance in FF liver only 24 hours after intracardiac injection (Figure 
6, G and H). In contrast to tumor growth, however, CPT1 gene deletion had no effect on cancer cell migration to 
steatotic liver, indicating it is likely not mitochondria based (Supplemental Figure 7).
Discussion
Obesity is associated with an increased incidence of  primary and metastatic breast and other cancers 
(17). Patients who are obese have poorer overall and breast cancer–specific survival (18). While a number 
of  mechanisms, including insulin resistance and inflammation, are invoked, the means by which obesity 
promotes tumorigenesis and compromises survival remain enigmatic (19–21).
Figure 4. Tumor promotes lipolysis of steatotic liver. (A) TG in control or FF liver explants cultured with or without Bo1 cells. n = 6. (B) Expression of 
ATGL and HSL in control or FF liver explants cultured with Bo1 cells. n = 4. (C) FFA in control or FF liver explants cultured with or without Bo1 cells. n 
= 6. (D) PET scan of 11C-palmitate uptake by control or FF liver 10 days after Bo1 intracardiac injection. (E) 11C-palmitate uptake quantification. n = 4. 
SUV, standardized uptake value. (F) FATP1 mRNA expression in cancer cells exposed to control or steatotic liver–conditioned medium. n = 3. Data are 
presented as mean ± SD. *P < 0.05, ***P < 0.001 as determined by unpaired 2-tailed t test (B, E, and F) or 2-way ANOVA test with analysis of variance 
with Holm-Šidák multiple-comparisons test (A and C).
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The skeleton is the most common site of  breast cancer metastasis, and we postulated that its marked 
bone accrual may render the FF mouse resistant to this complication. We found this not to be the case but 
observed a striking increase in metastasis to livers of  these animals and others that are steatotic regardless 
of  whether they are lipodystrophic or obese. Melanoma also abundantly metastasized to steatotic livers, 
indicating the fatty organ’s neoplastic predisposition goes beyond adenocarcinoma of  the breast.
Because of  the endemic nature of  the metabolic syndrome, NAFLD is estimated to be present in 
approximately 25% of  Americans (22). The prevalence of  NAFLD in patients with breast cancer is even 
higher, in one study reaching 72% of  those treated with systemic therapy (23). Given the prevalence of  
hepatic metastasis in breast cancer and steatosis, we were surprised by the paucity of  information regarding 
the relationship of  the 2 conditions in patients. One clinical study suggests steatosis restricts liver metastasis 
(24), but another claims it is increased (25).
Histological examination of  the metastasis-bearing livers of  steatotic mice revealed a marked reduction 
in lipid droplets in hepatocytes abutting the tumor, suggesting their transfer to cancer cells, where they may 
serve as an energy source for tumor growth. The same histological features are present in metastasis-bear-
ing human steatotic liver. This model is consistent with relocation of  lipids from adipocytes to ovarian and 
breast cancer cells as well as melanomas to promote growth (26). In fact, proliferating cancer cells may pref-
erentially use exogenous fatty acids as their membrane lipid source (27). We therefore hypothesized that 
steatosis facilitates hepatic metastasis by providing lipid products as an energy source to tumors. Consistent 
with this conclusion, Seahorse analysis of  cancer cells, cultured with steatotic or normal liver, indicates 
β-oxidation is enhanced. Mitochondrial oxidation is also increased in other forms of  cancer (28), particu-
larly when lipids, derived from adipocytes, are transferred to malignant cells (29). The functional signifi-
cance of  enhanced β-oxidation in steatotic metastasis is supported by induced expression of  CPT1 in cancer 
cells cultured with steatotic liver. This enzyme promotes formation of  acyl carnitines by catalyzing transfer 
of  the acyl group of  a long-chain fatty acyl-CoA from CoA to l-carnitine. Confirming an essential role of  
oxidation, deletion of  CPT1 in Bo1 cells virtually eliminated the metastatic predisposition of  fatty liver.
The likelihood that a liver-residing tumor induces lipolysis in steatotic hepatocytes is fortified by 
the decline in TG content in FF liver cultured with Bo1 cells. In addition, while lipolytic enzymes are 
Figure 5. Steatosis promotes tumor growth. (A) Morphology of Bo1 cells cultured with Con or steatotic liver of FF mice in serum-free medium; left panel shows 
the normal Bo1 cells cultured with medium with 10% serum. Scale bar: 100 μm. (B and C) Bo1 cells were injected directly into livers of 2-month-old FF and control 
mice. Tumor burden was analyzed 8 days later: (B) in vivo BLI image and (C) quantification of tumor burden in liver. n = 3–5. (D) PCNA immunostaining of liver of 
control or FF mice 12 days after intracardiac injection of Bo1 cells. n = 3. Data are presented as mean ± SD. *P < 0.05, as determined by unpaired 2-tailed t test (C).
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diminished in naive FF liver, they are increased in the presence of  cancer. Additionally, while not estab-
lishing the incorporating cell is neoplastic, the fact that metastasis stimulates palmitate uptake suggests 
that by mechanisms to be discovered, tumor may stimulate lipolysis in steatotic liver, the products of  
which are incorporated into cancer cells to serve as substrates for β-oxidation. The accumulation of  
lipid droplets in Bo1 cells, juxtaposed to fatty hepatocytes, indicates that as in transfer of  adipocyte 
lipids to breast cancer, the hepatocyte lipolytic products may be metabolized upon incorporation or 
temporarily stored as TGs (29). We confirmed transfer of  lipids to tumor and their subsequent metabo-
lism by coculture of  BODIPY-bearing hepatocytes and Bo1 cells. Consistent with steatotic hepatocytes 
providing fatty acids to cancer cells, FF liver–conditioned medium selectively enhanced Bo1 expression 
of  FATP1, which promotes metastasis by transporting adipocytic lipids to metastatic melanoma (15).
Net metastasis reflects predisposition of  cancer to seed target organs and its subsequent proliferation. 
A number of  parameters, such as PCNA expression, establish that growth of  cancer, once seeded in fatty 
liver, is enhanced. It appears that steatotic liver also facilitates seeding of  breast cancer, as illustrated by the 
abundance of  tumor in FF mice and its absence in WT, only 24 hours after direct injection. The fact that 
CPT1 deletion in tumor cells virtually eliminates steatotic metastasis while not affecting migration suggests 
that β-oxidation provides the energy for tumor growth but not seeding.
Previous studies conclude that induction of  metastasis in steatotic liver is mediated by inflammation. 
This conclusion is likely most appropriate in the context of  nonalcoholic steatohepatitis as hepatic inflam-
mation tends to be minimal in most patients with typical NAFLD. Additionally, hepatocyte-produced serum 
amyloid A1 and A2, which promote formation of  a premetastatic niche in liver, in the context of  fibrosis and 
inflammation, is decreased in FF mice (30). CXCL12/CXCR4 and CXCL16/CXCR6 chemokine signaling 
also mediates breast cancer progression (31, 32). Although increased CXCL12 and CXCL16 gene expression 
were observed in fatty liver, deletion of  CXCR6 and CXCR4 in Bo1 cells failed to reduce metastasis (data 
not shown). Thus, while other factors, such as the low-grade inflammation of  obesity, may contribute to the 
predisposition of  murine NAFLD to metastasis, it is likely the predominant mechanism is lipid transfer.
Figure 6. Steatosis promotes metastatic tumor growth. (A) BrdU incorporation and (B) AKT and cyclin D1 immunoblot of Bo1 cells treated with lipids (100 μg/mL) 
from control or FF liver. n = 5. (C) Seahorse oxygen consumption rate (OCR) of Bo1 cells cocultured with control or fatty liver. n = 9. (D) Carnitine palmitoyltrans-
ferase 1 (CPT1) mRNA expression in Bo1 cells cocultured with control or FF liver. n = 4–5. (E) BLI analysis of FF liver 12 days after intracardiac injection of CRISPR 
control or CRISPR-CPT1–knockout Bo1 cells. n = 4–7. (F) Bo1 cells were cultured with control or FF liver explants in Transwell system and migrating cell number was 
analyzed. n = 4. (G and H) Two-month-old FF and control mice were injected intracardiacally with Bo1 cells. Tumor burden was analyzed by BLI 24 hours later: (G) 
ex vivo image of liver and (H) quantification of tumor burden in liver. n = 6. Data are presented as mean ± SD. *P < 0.05, ***P < 0.001 as determined by unpaired 
2-tailed t test (A, C, D, F, and H) or 1-way (E) ANOVA test with analysis of variance with Holm-Šidák multiple-comparisons test.
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We believe the present report is first to document that the products of  pathologically deposited lipids 
promote metastasis and do so in a primary organ of  tumor seeding. Given the similar histological features 
of  lipid distribution in human metastasis-bearing liver, there is a reasonable likelihood that our observa-
tions will translate to patients. If  so, the clinical implications are significant as this common metabolic 
disorder is preventable and reversible, and its diminution may reduce liver metastasis.
Methods
Mice. Adipoq-Cre, PPARγfl/fl, adiponectin–/–, and leptin–/– mice were purchased from The Jackson Laboratory. 
FF mice were generated by mating homozygous Lox-stop-Lox-ROSA-DTA mice (7) to those expressing adi-
poq-Cre. Adipocyte-specific PPARγ deletion mice were generated by mating PPARγfl/fl mice with adipoq-Cre 
(PPAR ADQ). Lox-stop-Lox-ROSA-DTA mice and PPARγfl/fl mice were used as control mice of  FF mice and 
PPAR ADQ mice, respectively. C57BL/6 and Leptin+/– mice were used as control mice of  adiponectin–/– and 
leptin–/– mice, respectively. Both FF and PPAR ADQ mice could not survive at room temperature after birth 
because of  lack of  BAT, so they were housed at thermoneutral condition (30°C) till weaning age (3 weeks 
old). All other mice were kept at 22°C on a 12-hour light/12-hour dark cycle. Although no sex differences 
existed in phenotype, female mice were exclusively used. Mice used in experiments were 8–16 weeks old.
For HFD-feeding studies, mice were fed with chow diet until age 8 weeks and thereafter were random-
ized into groups that were fed either chow diet or HFD (Research Diets Inc., catalog D12492) for 3 months. 
Metformin was purchased from MP Biomedicals and dissolved in mouse drinking water (2 g/L) (7). Fresh 
drinking water with metformin was changed daily for 2 months.
Cell lines and construction of  gene deletion cells and mCherry-labeled cells. Mouse breast cancer cell lines 
PyMT-Bo1 (Bo1–), PyMT-Bo1-GFP-Luc (Bo1), and PyMT-B6 (B6) (estrogen receptor+ cells) (33); B16 
murine melanoma cell line (ATCC); human hepatocyte cell line (HepG2, ATCC); and platinum-E (Plat-E, 
ATCC) retroviral packaging cell line were maintained at DMEM with 10% FBS.
CRISPR guides were created using CRISPR Design (http://crispr.mit.edu). The sequence of  guide 
RNA (gRNA) for control and CPT1 deletion was 5′-ACACGCGCTTCCGCGGCCCGTTCAA-3′ and 
5′-GCCCAAAAGCAACGGAATCG-3′, respectively. gRNAs were subcloned into the lentiCRISPR V2 
system (34), and viruses were then infected into Bo1 cells. Puromycin selection was used to obtain 
control clones and clones deficient for CPT1. The gene deletion was determined by T7E1 assay with T7 
Endonuclease I (New England BioLabs, catalog M0302).
Retroviral plasmid pMX-RFP-mCherry was transfected transiently into Plat-E packaging cells using 
PolyJet in vitro DNA transfection reagent (SignaGen Laboratories, catalog SL100688). Virus was collected 
48 hours after transfection. Bo1 cells were infected with virus for 24 hours in the presence of  4 μg/mL poly-
brene (MilliporeSigma). Cells were selected in the presence of  2 μg/mL puromycin for 3 days before use.
Mouse tumor models. For systemic administration of  cancer, the left ventricular chamber of  2-month-old 
mice was injected with 1 × 105 PyMT-Bo1-GFP-Luc cells or B16 murine melanoma cells in 50 μL PBS as 
described previously (35). For direct liver injection, livers of  2-month-old mice were surgically exposed. 
Fifty thousand PyMT-Bo1-GFP-Luc cells in 10 μL PBS were injected directly into the liver using an insulin 
syringe with 29-gauge needle. BLI was used to quantify the tumor at indicated times after injection.
Bioluminescence imaging. For BLI of  live animals, as previously described (35), mice were injected intra-
peritoneally with 150 μg/g d-luciferin (Biosynth Carbosynth) in PBS, anesthetized with 2.5% isoflurane, 
and imaged with a charge-coupled device camera-based BLI system (IVIS 100; Caliper Life Sciences; expo-
sure time 1–60 seconds, binning 8, field of  view 12, f/stop 1, open filter, anterior side). Signal was displayed 
as photons/s/cm2/steradian. ROIs were defined manually around the legs using Living Image (Perkin-
Elmer) and Igor Pro Software (Version 2.50, WaveMetrics).
Fat transplantation. Mature fat depots were transplanted as described before (7). Two-month-old FF 
mice were anesthetized with isoflurane. Donor WAT fat pads from 6- to 8-week-old WT mice were cut into 
100–150 mg pieces. The grafts were implanted subcutaneously through small incisions in shaved skin of  the 
back, with 1 piece per incision. Six pieces of  fat graft were implanted into each FF mouse. After surgery the 
mice were housed individually for a week and then 5 mice per cage. Mice were injected with tumor cells 6 
weeks after transplantation.
Immunoblotting. Cultured cells were washed twice with ice-cold PBS and lysed in RIPA buffer (Mil-
liporeSigma) containing 1× protease inhibitor cocktail (Roche cOmplete). After incubation on ice for 10 
minutes, cell lysates were clarified by centrifugation at 21,000g at 4°C for 10 minutes. Then, 40 μg of  total 
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lysates were subjected to 10% SDS-PAGE and transferred onto PVDF membranes. Filters were blocked in 
0.1% casein in PBS for 1 hour and incubated with primary antibodies (phospho-Akt catalog 4056, AKT 
catalog 9272, cyclin D1 catalog 2922, all from Cell Signaling Technology) at 4°C overnight followed by 
probing with fluorescence-labeled secondary antibodies (Jackson ImmunoResearch Laboratories). Proteins 
were detected with the Odyssey Infrared Imaging System (LI-COR Biosciences).
Immunohistochemical staining. Paraffin sections (5 μm) from mice were rehydrated and treated with 0.3% 
hydrogen peroxide in methanol for 15 minutes to suppress endogenous peroxidase activity. Antigen retriev-
al was achieved by microwaving the sections in 10 mM citrate buffer for 10 minutes followed by gradual 
cooling to room temperature. Sections were incubated with primary PCNA antibody (PC10, Santa Cruz 
Biotechnology) overnight at 4°C. Immunostaining was detected using the Histostain-SP Broad Spectrum 
(DAB) kit (Thermo Fisher Scientific, catalog 95-9743).
Flow cytometry. To generate fluorescence-labeled lipids, HepG2 cells were incubated with fluorescent fat-
ty acid analog (C1-BODIPY 500/510 C12, Thermo Fisher Scientific, catalog D3823) for 24 hours. Thereafter, 
HepG2 cells were washed with PBS containing 0.2% fatty acid–free BSA to remove extracellular fatty acids and 
cocultured with mCherry-labeled Bo1– cells. After 0, 3, 6, 12, and 24 hours’ coculture, the cells were collected 
and stained with the dead cell exclusion dye ZombieUV (1:600; BioLegend) in PBS. Cells were then incubated 
with 10 mg/mL FcBlock (clone 24G.2; BD Biosciences) in PBS containing 2.5% heat-inactivated FBS and 2 
mM EDTA before being stained for flow cytometric analyses, as previously described (36, 37). Mouse anti–
human HLA-A,B,C Antibody (BioLegend; clone W6/32; 1:200) was used to stain HepG2 cells. Flow cytomet-
ric analyses were performed with FlowJo (version 10), and cells were gated on singlets and live cells.
Confocal microscopy. HepG2 cells were treated with BODIPY 500/510, then cocultured with mCher-
ry-labeled Bo1– cells on microscope cover glass (Fisherbrand, Thermo Fisher Scientific, catalog 12-545-80). 
After 3 hours of  coculture, cells were rinsed with PBS and fixed with 4% formalin. Then the cells were ana-
lyzed with a Zeiss LSM880 laser scanning confocal microscope (Carl Zeiss Inc.) equipped with a ×63, 1.4 
numerical aperture Zeiss Plan Apochromat oil objective. The argon (excitation 488 nm) and helium neon 
(excitation 543 nm) lasers were used in obtaining confocal Z slices of  0.9 μm through the entire height of  
cells. ImageJ software (NIH) was used to analyze the images.
Electron microscopy. Tumor tissues from Con and FF livers that had been intracardially injected with 
Bo1 cells for 10 days were cut into about 2 mm size and fixed at 5% glutaraldehyde in 0.16 M collidine 
buffer overnight. Then samples were washed in sodium cacodylate buffer at room temperature and post-
fixed in 1% osmium tetroxide (Polysciences Inc.) for 1 hour. Samples were then rinsed extensively in 
distilled H2O (dH2O) before en bloc staining with 1% aqueous uranyl acetate (Ted Pella Inc.) for 1 hour. 
Following several rinses in dH2O, samples were dehydrated in a graded series of  ethanol and embedded 
in Eponate 12 resin (Ted Pella Inc.). Sections of  95 nm were cut with a Leica Ultracut UCT ultrami-
crotome (Leica Microsystems Inc.), stained with uranyl acetate and lead citrate, and viewed on a JEOL 
1200 EX transmission electron microscope (JEOL USA Inc.) equipped with an AMT 8-megapixel digital 
camera and AMT Image Capture Engine V602 software (Advanced Microscopy Techniques).
Liver lipid extraction. Liver lipid was extracted following the standard chloroform/methanol/H2O pro-
tocol (38). Briefly, fresh liver was homogenized on ice, and PBS-methanol (1:1, v/v) was added, followed 
by addition of  the same volume of  chloroform. The mixture was kept at –20°C for at least 30 minutes. The 
bottom layer was dried with nitrogen and lipids extracted with toluene-isopropanol (1:3, v/v).
Liver lipid measurement. Liver explants (50 mg) from Con and FF mice were cocultured with Bo1 cells 
in Transwell plates. After 24 hours’ coculture, liver explants were collected and sent to the metabolic core, 
Washington University School of  Medicine, for the analysis of  triglyceride and FFAs.
11C-palmitate PET. Ten days after intracardiac injection of  Bo1 cells, FF mice were subjected to PET 
imaging using cross-calibrated Siemens Inveon PET/CT or Focus F220 scanners. Mice were secured in a 
custom-designed acrylic restraining device and placed inside the field of  view of  the scanners. A 30-min-
ute dynamic PET image acquisition was initiated immediately preceding a bolus injection of  11C-palmitate 
via the tail vein. Dynamic images were reconstructed using Ordered Subsets Expectation Maximization 
algorithm. Images were analyzed by drawing ROIs on livers to ascertain in vivo measures of  fatty acid (via 
11C-palmitate) metabolism. Data derived from ROIs were normalized to standardized uptake values (SUV = 
activity × [weight of  mouse/injected dose]) to account for differences in injected dose and weight of  mice.
RNA isolation and qPCR. Total RNA from fresh liver or cells was extracted using TRIzol (Invitrogen, 
Thermo Fisher Scientific) following RNA purification with RNeasy RNA purification kit and RNase 
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free DNase digestion (QIAGEN, catalog 74104). Complementary DNA was synthesized from RNA (1 
μg) using the iScript cDNA Reverse Transcription kit (Bio-Rad, catalog 1708890) according to the man-
ufacturer’s instructions. Real-time PCR was performed using the SYBR Green Master Mix kit (Applied 
Biosystems, Thermo Fisher Scientific, catalog A25741) and the gene-specific primers listed in Table 1. 
GAPDH was used as a housekeeping gene. PCRs for each sample were performed with 7500 Fast Real-
Time PCR System (Applied Biosystems, Thermo Fisher Scientific) using the comparative threshold cycle 
method for relative quantification.
Cell mitochondrial stress (Seahorse) assay. The simultaneous measurements of  cellular OCR (in pmol/
min) and ECAR (in mpH/min) were performed with a Seahorse Bioscience XF96 Extracellular Flux 
Analyzer. After Transwell coculture with liver for 24 hours, 50,000 Bo1 cells/well were plated on Seahorse 
96-well plates 6 hours before assay. Baseline OCR and ECAR were measured at 5 time points, followed by 
the sequential injection of  oligomycin (final concentration, 1 μM), FCCP (final concentration, 2 μM), and 
a mixture of  rotenone (final concentration, 1 μM) and antimycin A (final concentration, 1 μM).
Cell migration assay. Migration assay was performed using 8 μm Transwell filters (Costar, Corning). 
Briefly, 10 mg of  fresh liver tissues were placed in the lower chamber with DMEM and 1 × 105 Bo1 cells in 
the upper wells; 24 hours later, the cells in the inserts were fixed with 70% ethanol and cells attached to the 
top surface of  the membrane were removed with cotton swabs. Residual cells on the bottom of  the insert 
membrane were stained with 1% crystal violet (Thermo Fisher Scientific). After elusion with 1% SDS, the 
crystal violet dye was measured by absorbance at 595 nm.
Statistics. Data are presented as mean ± SD. Differences between groups were evaluated by unpaired 
2-tailed Student’s t test or 1-way or 2-way ANOVA test with ANOVA with Holm-Šidák multiple-compari-
sons test. All experiments were repeated at least 2 times.
Study approval. Animal work was performed according to the policies of  the Animal Studies Committee 
at Washington University School of  Medicine in St. Louis. Mice were analyzed under approved protocols 
and were provided appropriate care while undergoing research that complied with the standards in the 
Guide for the Use and Care of  Laboratory Animals (National Academies Press, 2011) and the Animal Welfare 
Act. The unidentified patient biopsy slide did not require IRB approval.
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